Abrocitinib Market Drug Insight and Market Forecast - 2032

“Abrocitinib Market Drug Insight and Market Forecast - 2032” report provides comprehensive insights about abrocitinib for Atopic Dermatitis (AD) in the seven major markets. A detailed picture of the abrocitinib for atopic dermatitis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the abrocitinib for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the abrocitinib market forecast analysis for atopic dermatitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.

Drug Summary

Abrocitinib (PF-04965842) is an oral, small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 modulates multiple cytokines involved in the pathophysiology of AD, including interleukin (IL)-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP). Abrocitinib reversibly inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site (FDA, 2022).

The US FDA approved Cibinqo for the treatment of adults living with refractory, moderate-to-severe AD whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable, in January 2022. The drug is approved at the recommended doses of 100 mg and 200 mg, with the 200 mg dose being recommended for patients who are not responding to the 100 mg dose. Additionally, a 50 mg dose was approved to treat moderate-to-severe AD specifically in patients with moderate renal impairment (kidney failure), certain patients receiving treatment with inhibitors of cytochrome P450 (CYP) 2C19, or patients who are known or suspected to be poor metabolizers of CYP2C19. In addition to receiving regulatory approval in the US, CIBINQO has received marketing authorization in the European Union, Great Britain, Japan, Korea, the United Arab Emirates, Norway, Iceland, and Singapore.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the abrocitinib description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.
• Elaborated details on abrocitinib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the abrocitinib research and development activities in atopic dermatitis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around abrocitinib.
• The report contains forecasted sales of for atopic dermatitis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.
• The report also features the SWOT analysis with analyst views for abrocitinib in atopic dermatitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Abrocitinib Analytical Perspective

In-depth Abrocitinib Market Assessment

This report provides a detailed market assessment of abrocitinib for atopic dermatitis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

Abrocitinib Clinical Assessment

The report provides the clinical trials information of abrocitinib for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence abrocitinib dominance.
• Other emerging products for atopic dermatitis are expected to give tough market competition to abrocitinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of abrocitinib in atopic dermatitis.
• This in-depth analysis of the forecasted sales data of abrocitinib from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the abrocitinib in atopic dermatitis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of abrocitinib?
• What is the clinical trial status of the study related to abrocitinib in atopic dermatitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the abrocitinib development?
• What are the key designations that have been granted to abrocitinib for atopic dermatitis?
• What is the forecasted market scenario of abrocitinib for atopic dermatitis?
• What are the forecasted sales of abrocitinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to abrocitinib for atopic dermatitis?
• Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?

This product will be delivered within 2 business days.